Sign in

CIK 0001799448 · Non-accelerated filer<br>Smaller reporting company

Aligos Therapeutics, Inc.

Sign in to watch
Ticker
ALGS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
(800) 466-6059
Business address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2020-10-20 Novo Holdings A/S 10% owner Conversion · SERIES B -1 CONVERTIBLE PREFERRED STOCK −563,851 0
2020-10-20 Novo Holdings A/S 10% owner Conversion · SERIES B -2 CONVERTIBLE PREFERRED STOCK −241,219 0
2020-10-20 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner Conversion +1,335,048 1,335,048
2020-10-20 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner Conversion +571,143 1,906,191
2020-10-20 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner Conversion · Series B-1 convertible Preferred Stock −1,335,048 0
2020-10-20 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner Conversion · Series B-2 convertible Preferred Stock −571,143 0
2020-10-20 Woiwode Thomas Director Conversion +2,145,991 2,145,991
2020-10-20 Woiwode Thomas Director Conversion +198,839 2,344,830
2020-10-20 Woiwode Thomas Director Conversion +85,065 2,429,895
2020-10-20 Woiwode Thomas Director Conversion +463,959 463,959
2020-10-20 Woiwode Thomas Director Conversion +198,485 662,444
2020-10-20 Woiwode Thomas Director Purchase +200,000 $15.00 $3.0M 862,444
2020-10-20 Woiwode Thomas Director Conversion · Series A Preferred Stock −2,145,991 0
2020-10-20 Woiwode Thomas Director Conversion · Series B-1 Preferred Stock −198,839 0
2020-10-20 Woiwode Thomas Director Conversion · Series B-1 Preferred Stock −463,959 0
2020-10-20 Woiwode Thomas Director Conversion · Series B-2 Preferred Stock −85,065 0
2020-10-20 Woiwode Thomas Director Conversion · Series B-2 Preferred Stock −198,485 0
2020-10-20 Vivo Capital VIII, LLC 10% owner Conversion +1,885,611 1,885,611
2020-10-20 Vivo Capital VIII, LLC 10% owner Conversion +523,726 2,409,337
2020-10-20 Vivo Capital VIII, LLC 10% owner Conversion +224,054 2,633,391

Page 8 of 12 · 238 trades